Inhalon Biopharma Announces Positive Results from Study Demonstrating Superior Safety and Efficacy of its Inhaled Antibody Platform Over Systemic Dosing
The study upends prevailing thinking about inhaled antibody delivery by demonstrating that antibodies maintain their activity following nebulization and can be dosed uniformly to all parts of the respiratory tract, including the deep lung.
- The study upends prevailing thinking about inhaled antibody delivery by demonstrating that antibodies maintain their activity following nebulization and can be dosed uniformly to all parts of the respiratory tract, including the deep lung.
- It also shows that inhaled antibodies can achieve concentrations throughout the respiratory tract greatly exceeding the levels required to neutralize most acute respiratory viruses.
- The greater convenience, dose savings and reduced burden on healthcare infrastructure supports initiating inhaled antibody treatment at the earliest time possible.
- The much greater antibody concentrations achieved in the respiratory tract with inhalation suggests the potential for even greater therapeutic effect.